Helus Pharma (HELP) Stock Forecast: StockMap's 2-Week Call
HELP stock forecast: StockMap's model leans Underperform on Helus Pharma for the two weeks after the Nov 19 close, toward HELP trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 5 two-week windows on HELP since Aug 24; by chance, a call on the same dates was right 54% of the time.
Helus Pharma last closed at $6.78, -1.60% on the session.
Against the IVW growth benchmark the position is +0.73% over the forecast window.
Helus Pharma's market cap is $541.08M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -39 (too close to call).
Where HELP sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 2 bullish and 13 bearish.
Agreement across those insights is 87%.
22 daily calls for HELP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Helus Pharma in the 13th percentile on return on equity, where 100 is best.
Helus Pharma is classified under Health Care / Pharmaceuticals.
StockMap tracks Helus Pharma as the 71st largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Helus Pharma ranks 90th of 153 in the group, against a group median of -0.36.